Better High-Yield Dividend Stock: Pfizer vs. Amcor

Chris Arnold • 6 minute read
Reviewed by: Chris Arnold
Last updated Nov 21, 2026

Rulles from Getty Images

Key Takeaways

  • Pfizer and Amcor both yield 6%, and Amcor raised its quarterly dividend to $0.66 a share on Nov. 4.
  • With the yields this close, the better choice is the company whose cash flow and balance sheet can more easily carry its dividend.
  • Pfizer’s dividend took 89% of its free cash flow over the twelve months to June, while Amcor’s took 156% over the twelve months to September.
  • Amcor’s net debt is 3.9x EBITDA, about twice Pfizer’s 1.9x, and it’s aiming for 3x by the end of 2027.

Amcor (AMCR) raised its quarterly dividend by a penny on Nov. 4, to $0.66 a share, the same day it lowered its earnings outlook for the rest of 2026. That leaves its 6.0% yield a hair under the 6.1% of Pfizer (PFE), which raised its own 2026 guidance a day earlier.

For an income investor, the question is which of those checks has more cash behind it.

MetricPfizer (PFE)Amcor (AMCR)
Dividend yield6.1%6.0%
Annual dividend$1.72$2.64
Dividend growth, fiscal 2020-20252.5% a year2.1% a year
Cash dividend payout ratio (TTM)89%156%
Net debt / EBITDA1.9x3.9x
Interest coverage7.0x3.1x
Forward P/E10x11x

Source: TIKR and StockAnalysis, at today’s prices. Payout ratios cover the twelve months to June 28, 2026 (Pfizer) and Sept. 30, 2026 (Amcor).

6 safe dividend stocks paying retirees 6%+ yields

There are over 100 stocks paying 6%+ annual dividends today.

But after an extensive investment review leveraging TIKR’s proprietary data, we now believe only six of them are truly safe for retirees.

They’re all yours as part of our new investment report. Learn more about how to get access right here.

Pfizer’s new drugs are carrying the load

Pfizer’s third-quarter revenue of $16.6 billion was relatively flat year over year operationally. Its launched and acquired products grew 32%, while Paxlovid fell 63% and Comirnaty 29%. Management still raised its 2026 guidance to $62.0-$64.0 billion of revenue and $2.95-$3.05 of adjusted EPS.

The cash behind the dividend has been thinner since the COVID windfall faded. Free cash flow fell from $26.0 billion in fiscal 2022 to $9.08 billion in fiscal 2025, which was short of the $9.77 billion Pfizer paid in dividends:

Bar chart from TIKR of Pfizer's free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025.
Pfizer (PFE): free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025 (TIKR)

Over the twelve months to June 28, 2026, its cash dividend payout ratio was a thin 89%. CEO Albert Bourla said on the company’s August call that “even the most stretched scenarios that we are running, we will be able to maintain our dividend.” That’s a promise to keep the check, even though growth has been slow: 2.5% a year from fiscal 2020 to fiscal 2025, from $1.52 to $1.72 a share.

The main risk is patents. Ibrance, Xtandi and Eliquis outside the US lose exclusivity over the next several years. Pfizer puts the hit from recent and expected generic and biosimilar competition at about $1.1 billion of lost revenue.

Amcor’s cash is still catching up

Amcor’s sales are growing faster than Pfizer’s, but its cash hasn’t kept up. September-quarter sales rose 7% to $6.13 billion, with volume up 1%. Amcor also trimmed its adjusted EPS outlook for the rest of 2026 to $1.70-$1.80 from $1.80-$1.90, because it is passing on higher energy and distribution costs more slowly than they are rising.

Free cash flow covered the dividend in the year ended June 2026, but only just:

Bar chart from TIKR of Amcor's free cash flow vs. common dividends paid, $ millions, fiscal 2017–2026 (years to June).
Amcor (AMCR): free cash flow vs. common dividends paid, $ millions, fiscal 2017–2026 (years to June) (TIKR)

That year’s cash dividend payout ratio was 97.2%, and dividends have taken at least 86% of free cash flow every year since the year ended June 2023. Over the twelve months to Sept. 30, the ratio jumped to a risky 156%. Free cash flow was negative $820 million in the September quarter, against negative $343 million a year earlier. Management ties a working-capital hit of about $500 million to the Middle East conflict and expects to recover it by the end of 2027. Meanwhile, net debt rose to $14.01 billion at Sept. 30 from $12.90 billion at June 30.

So which dividend wins?

Pfizer is the better high-yield dividend stock. It yields a touch more, and its dividend has grown a bit faster. Its free cash flow also covers the check, which Amcor’s hasn’t done over the last twelve months.

Pfizer has the stronger balance sheet, too, with interest coverage of 7.0x against Amcor’s 3.1x. Amcor’s leverage, meanwhile, has run at 2.9x or more every year since the year ended June 2022:

Bar chart from TIKR of Amcor's net debt to EBITDA (x), fiscal 2022-2026 (years to June).
Amcor (AMCR): net debt to EBITDA (x), fiscal 2022-2026 (years to June) (TIKR)

Amcor’s leverage spiked to 6.4x in the year ended June 2025, after the Berry deal, before falling back to 3.6x a year later.

Pfizer pays more over time, too. $10,000 in Pfizer pays $610 a year today and about $762 in year 10 at its five-year growth rate. The same $10,000 in Amcor pays $600 now and about $722 in year 10, and at those rates Amcor never catches up.

This isn’t to say Amcor’s dividend is in danger. It just raised the check, and management said on the Nov. 4 call that it is “targeting leverage of approximately 3x by year-end, while continuing to modestly increase the dividend.” It’s just that Pfizer can keep paying from the cash it makes today, while Amcor’s dividend depends on a plan that’s still playing out.

Of course, Pfizer has its own test coming. CFO Cecile Guegan said its 2027 guidance will reflect two of its products entering Medicare’s negotiated prices that year.

Forget Pfizer: 6 safe 6%+ dividend yields you can buy right now

Dividends can hold the key to enormous wealth. But only if you buy the right ones.

Picking the right high-yield dividend stock can be the difference between a dream retirement…and scraping by every month, waiting for the next Social Security check to clear.

We’ve identified six stocks yielding 6%+ that we believe every retiree should know about right now. (And Pfizer isn’t one of them.)

Learn more here.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required